×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Maps
Videos
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
AACR Annual Meeting 2018 - Wynzora, Almirall
The Pharma Letter
New launches going well for Almirall at the start of 2023. 09-05-2023. Spanish dermatology company Almirall has recorded net sales of 230 million euros...
3 days ago
Anna López-Ferrer, MD, PhD, and Volker Koscielny, MD, MBA, Share Highlights From Almirall's 15th Skin Academy
Dermatology Times
Earlier this month, Almirall hosted its 15th annual Skin Academy meeting in Barcelona, Spain. The 2-day conference brought together...
1 week ago
Almirall and Microsoft partner on AI-powered drug discovery in dermatology
News-Medical
Almirall S.A., a global pharmaceutical company focused on medical dermatology, announced today a strategic partnership with Microsoft to...
3 months ago
What Is Almirall's (BME:ALM) P/E Ratio After Its Share Price Tanked?
Yahoo Movies Canada
Unfortunately for some shareholders, the Almirall (BME:ALM) share price has dived 30% in the last thirty days. That...
4 days ago
Almirall licenses IL-21 antibody from Novo Nordisk
Pharmaceutical Technology
Almirall has signed a licensing agreement for the acquisition of worldwide rights to Novo Nordisk's IL21-hindering antibody NN-8828.
2 months ago
Novo Licenses to Almirall Potential First-in-Class Antibody Candidate
BioSpace
Almirall will have exclusive global rights to develop and commercialize the anti-IL-21 monoclonal antibody NN-8828 in several fields,...
2 months ago
Almirall signs yes-nonsense deal with Eloxx for $3M upfront
Fierce Biotech
Almirall is handing over $3 million for Eloxx Pharmaceuticals' molecule for a pair of rare skin diseases just before the drug enters the...
1 month ago
Almirall gains rights to ZKN-013, potential treatment for RDEB, JEB
Epidermolysis Bullosa News
Almirall has licensed rights to ZKN-013, an experimental oral treatment for some types of epidermolysis bullosa, from prior developer Eloxx.
1 month ago
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology
Business Wire
Almirall and etherna Enter Into a Multi-Target Alliance to Develop mRNA-based Therapies in Medical Dermatology ... “At Almirall, we always look...
4 months ago
Almirall drills home message about psoriasis' mental health toll, reupping miniseries for awareness day
Fierce Pharma
Spain's Almirall stepped up its communications about the need to consider the impact of psoriasis on the well-being and mental health of...
6 months ago